2022-06-09 | NDAQ:SOPH | Press release

BOSTON and LAUSANNE, Swiss, June 9, 2022 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH), the August Pi i Sunyer Institute for Biomedical Investigations (IDIBAPS) of Barcelonaand Spain’s Diagnóstica Longwood announced today at the European Hematology Association Congress in Vienna that they have combined their expertise to develop a novel chronic lymphocytic leukemia (CLL) solution to advance CLL care. This collaboration will unify the wide variety of current guideline recommendations into a single application aimed at improving CLL characterization and CLL research practices in the Iberian Peninsula.

SOPHiA GENETICS has already facilitated the analysis of one million genomic profiles via the SOPHiA DDM™ platform, including a significant number of onco-haematological diseases such as acute myeloid leukemia and lymphomas. The platform calculates a wide range of genomic variants needed to continuously refine machine learning algorithms designed to accurately detect rare and difficult cases. The growing number of users in the SOPHiA DDM™ community can share and access information by extracting relevant detected signals from noise, ultimately saving time and making more informed decisions.

New CLL solution helps advance chronic lymphocytic leukemia research using genomic analysis. This could lead to better detection of the disease, which accounts for 25-30% of all leukemia cases in Western countries and affects more than 100,000 people worldwide each year.[1], and ultimately improve patient care. Thanks to the SOPHiA DDM™ and IDIBAPS platform, hematopathologists can now access recommendations on the mutation status of TP53, immunoglobulin (IG) gene rearrangements and their somatic hypermutation status, while benefiting from the identification of 23 CLL-specific genes for SNVs, InDels and CNVs, including NOTCH1, SF3B1, AT MIGLV3-21, BTK, PLCG2, BCL2del13q14 and trisomy 12, all in one NGS workflow.

The new CLL solution has already been used routinely in Spainwith other opportunities across the country, and in Latin America through the distribution channels of Diagnóstica Longwood.

“We are proud to work with some of the most renowned experts in the field of chronic lymphocytic leukemia research around the world. This partnership is a great example of how combining advanced data analytics with emerging LLC strategies can evolve the possibilities of data-driven research. medicine forward,” said Lara Hashimotocommercial director of SOPHiA GENETICS.

“It is a great satisfaction to see how, thanks to the partnership with SOPHiA GENETICS and Diagnóstica Longwood, we will be able to transfer into clinical practice the relevant information generated over so many years in CLL research using a simple and robust test,” said Elías Campo, Principal Investigator and Director of IDIBAPS.


SOPHiA GENETICS (Nasdaq: SOPH) is a health technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life science research. He is the creator of the SOPHiA DDM™ platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal datasets and different diagnostic modalities. The SOPHiA DDM™ platform and associated solutions, products and services are currently used by more than 790 hospitals, laboratories and biopharmaceutical institutions worldwide. For more information, visit SOPHiAGENETICS.COMor log on to Twitter, LinkedIn and instagram. Where others see data, we see answers.


The August Pi i Sunyer Institute for Biomedical Research (IDIBAPS) is a biomedical research center of excellence that tackles the most common diseases in our environment. It is a public consortium made up of the Catalan government (Generalitat de Catalunya), Hospital Clínic Barcelonathe Faculty of Medicine and Health Sciences of University of Barcelona and the CSIC Biomedical Research Institute of Barcelona.

Around 1,500 professionals are organized into around 100 research groups. IDIBAPS undertakes translational research. It aims to ensure that questions arising at the bedside are answered in the lab and that advances made in the lab are quickly applied to patients. With more than 1,200 articles published each year, it is the leading biomedical research center in Spain.

About Diagnostica Longwood SL

Diagnóstica Longwood is a Spanish company founded 30 years ago with the aim of satisfying the needs of the laboratory professional, specializing over the years in molecular diagnostics. Through innovation, continuous improvement and continued commitment to the integration of new technologies, the company has become a leading distributor in transplantation immunology, genetics, hematology, oncology and blood banks, among others. , offering its customers an integrated, personalized and efficient service. Thanks to the dynamic, versatile and highly qualified human resources of Diagnóstica Longwood, it is able to complete the puzzle of commercial excellence, which allows the professional to optimize the entire process and obtain the best results. Its product catalog includes leading brands in molecular diagnostics such as SOPHiA GENETICS.

La Diagnóstica Longwood stands out for its large team of highly qualified professionals, who respond quickly and efficiently to the needs of customers, both in the national territory and abroad. This personalized attention is part of the team’s DNA and one of the company’s strategic values.

For more information, visit DLONGWOOD.COMor log on to LinkedIn.

SOPHiA GENETICS products are for research use only and should not be used in diagnostic procedures unless otherwise specified. The information in this press release relates to products that may or may not be available in different countries and, where applicable, may or may not have received marketing approval or clearance from a government regulatory body for different indications for use. please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS forward-looking statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS’ future operating results and financial condition, business strategy, products and technology, and plans and management objectives for future operations, are forward-looking. research statements. Forward-looking statements are based on the beliefs and assumptions of SOPHiA GENETICS’ management and on information currently available to its management. These statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied by the forward-looking statements due to a variety of factors, including those described in documents filed by SOPHiA GENETICS with the United States Securities and Exchange Commission. No assurance can be given that these future results will be achieved. These forward-looking statements contained in this press release speak only as of the date hereof. SOPHiA GENETICS expressly disclaims any obligation or undertaking to update any forward-looking statements contained in this press release to reflect any change in its expectations or any change in events, conditions or circumstances on which such statements are based, except as required to do so. do so by applicable law. No representation or warranty (express or implied) is made as to the accuracy of these forward-looking statements.

[1] 1. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal Cancer Statistics, 2020. CA Cancer J Clin. 2020;70:145–164. doi: 10.3322/caac.21601.

Media Contact:

Sophie Raymond

+41 79 863 11 10


Logo- https://mma.prnewswire.com/media/1835876/SOPHiA_GENETICS_Logo.jpg

Quote Show original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-launches-new-solution-to-advance-chronic-lymphocytic-leukemia-care-in-collaboration-with-idibaps-301564374.html


Comments are closed.